Jan 30, 2024
Sound Pharma to present positive interim data from its Phase 2b Cystic Fibrosis STOP Ototoxicity Trial
Aug 31, 2020
FDA allows Sound Pharmaceuticals to test SPI-1005 as a novel treatment for COVID-19
Jul 30, 2020
Sound Pharmaceuticals files IND to test SPI-1005 in Phase 2 COVID-19 trials
Jun 08, 2020
Sound Pharma advances pivotal Phase 3 clinical trials in Meniere's Disease
May 04, 2020
University of Oxford and Sound Pharmaceuticals complete Phase 2 Bipolar Disorder Study with SPI-1005
Sep 18, 2019
FDA grants Fast Track Designation for SPI-1005 in the Treatment of Meniere's Disease
Jun 25, 2019
Sound Pharmaceuticals announces positive topline results from the SPI-1005 Phase 2b Meniere's Disease clinical trial
Mar 06, 2019
Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere's Disease clinical trial
Jan 14, 2019
Sound Pharmaceuticals advances Phase 2 hearing loss clinical trial in Cystic Fibrosis
Sep 25, 2018
Sound Pharmaceuticals to present initial data on the STOP Ototoxicity Study at Cystic Fibrosis Conference
Nov 01, 2017
University of Oxford and Sound Pharmaceuticals begin Phase 2 clinical trial on novel treatment for bipolar disorder
Oct 03, 2017
Sound Pharmaceuticals announces positive Phase 1b results and the start of a Phase 2b clinical trial in Meniere's Disease
Sep 25, 2017
Sound Pharmaceuticals initiates STOP Ototoxicity Study in Cystic Fibrosis
Jun 27, 2017
Sound Pharmaceuticals completes enrollment on Meniere's Disease clinical trial